Detalles de la búsqueda
1.
A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
Cancer
; 130(S8): 1524-1538, 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38515388
2.
Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.
Cancer Sci
; 114(2): 665-679, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36178064
3.
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).
BMC Med
; 21(1): 72, 2023 02 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36829154
4.
A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
BMC Cancer
; 21(1): 640, 2021 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34051733
5.
Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.
Hum Mol Genet
; 25(3): 620-9, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26732429
6.
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Br J Cancer
; 118(5): 654-661, 2018 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438373
7.
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
Invest New Drugs
; 36(2): 315-322, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29134432
8.
Factors influencing the attitudes of Chinese cancer patients and their families toward the disclosure of a cancer diagnosis.
J Cancer Educ
; 30(1): 20-5, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24931287
9.
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.
Mol Cancer
; 13: 219, 2014 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25241075
10.
Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.
J Cancer Res Clin Oncol
; 150(2): 42, 2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280966
11.
Efficacy and survival outcomes of alectinib vs. crizotinib in ALKpositive NSCLC patients with CNS metastases: A retrospective study.
Oncol Lett
; 27(5): 224, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38586212
12.
Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma.
Int Immunopharmacol
; 129: 111684, 2024 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38364745
13.
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
J Thorac Oncol
; 19(6): 912-927, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280448
14.
The genetic polymorphisms of intercellular cell adhesion molecules and breast cancer susceptibility: a meta-analysis.
Mol Biol Rep
; 40(2): 1855-60, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23079714
15.
Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody.
J Immunother Cancer
; 11(2)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36854570
16.
Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
J Cancer Res Clin Oncol
; 149(4): 1443-1451, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35482078
17.
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
J Immunother Cancer
; 11(2)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36808075
18.
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
; 29(23): 4830-4843, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37449971
19.
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
J Thorac Oncol
; 18(5): 628-639, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36646210
20.
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
Lung Cancer
; 171: 56-60, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35917647